Deals Of The Week: Stiefel/Welichem, Bayer/Covance, Ensemble/Genentech
Executive Summary
Activist investor Carl Icahn is at it again, announcing plans May 30 to propose a minority slate of new board members for patent-cliff-challenged specialty pharma Forest Laboratories.
You may also be interested in...
Forest’s Solomon Holding Firm As Icahn Presses Second Consecutive Proxy Fight
In July 9 letter to Icahn, Forest CEO asks why the activist investor hasn’t offered strategic ideas, rather than threaten another fight over board control.
GSK’s Stiefel Adds Psoriasis/Atopical Dermatitis Candidate In Licensing Deal
For about $34 million, Stiefel gets development and commercialization rights in most of the world to a novel, non-steroidal, topical anti-inflammatory compound in Phase II.
Bristol-Myers Taps Academia To Help Research Immuno-Oncology Pipeline
Inspired by the correlative research during the clinical trials for Yervoy, BMS teams up with ten institutions from across the globe to find biomarkers in post-response data.